DYN Stock Analysis: Buy, Sell, or Hold?
DYN - Dyne Therapeutics, Inc. Common Stock
$17.29
-0.99 (-5.42%)
▼
5d:
-1.82%
30d:
-13.16%
90d:
+11.26%
BUY
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Distribution
DYN is up 4.2% this week, but smart money is buying puts. Top strike: $22.5 2026-07-17 with 32 OI. Put ratio: 97% View Scanner →
Strength: 6.8/10
Get Alerted When DYN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DYN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DYN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DYN is currently trading at $17.29, which is considered oversold relative to its 30-day fair value range of $17.65 to $19.52.
Technical Outlook: Technically, DYN is showing sideways momentum. The price is currently testing key support at $16.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: DYN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $38.19 (+120.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DYN is showing sideways momentum. The price is currently testing key support at $16.97. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.4% recently.
Market Sentiment: DYN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $38.19 (+120.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$17.65 -
$19.52
Company Quality Score
57/100
(HOLD)
Options IV Signal
4th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 4th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.4%)
- BULLISH: Trading 120.9% below Wall St target ($38.19)
Trading Range Analysis
30-Day Trading Range
$17.65 -
$19.52
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.39
(19.6%)
Support & Resistance Levels
Support Level
$16.97
Resistance Level
$18.99
Current Trend
Sideways
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.85
Wall Street Target
$38.19
(+120.9%)
Share & Embed Analysis
Last updated: May 18, 2026 7:29 AM ET
Data refreshes hourly during market hours. Next update: 8:29 AM
Data refreshes hourly during market hours. Next update: 8:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DYN showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jason P Rhodes
SELL
287956 shares
2026-04-22
Jason P Rhodes
SELL
274297 shares
2026-04-21
Jason P Rhodes
SELL
272049 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$103 | 55 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$126 | 48 HOLD |
Advanced DYN Option Strategies
Professional options setups generated by AI based on today's DYN price and gamma walls.